Absci reports business updates and fourth quarter and full year 2023 financial and operating results

Initiated ind-enabling studies for abs-101, a potential best-in-class anti-tl1a antibody entered into collaboration with astrazeneca for up to $247m in deal value, plus royalties strengthened balance sheet raising approximately $86m in gross proceeds through underwritten common stock offering vancouver, wash. and new york, march 21, 2024 (globe newswire) -- absci corporation (nasdaq: absi), a data-first generative ai drug creation company, today reported financial and operating results for the fourth quarter and year ended december 31, 2023.
ABSI Ratings Summary
ABSI Quant Ranking